MX375402B - Nuevo anticuerpo anti-dengue de espectro completo. - Google Patents
Nuevo anticuerpo anti-dengue de espectro completo.Info
- Publication number
- MX375402B MX375402B MX2016009991A MX2016009991A MX375402B MX 375402 B MX375402 B MX 375402B MX 2016009991 A MX2016009991 A MX 2016009991A MX 2016009991 A MX2016009991 A MX 2016009991A MX 375402 B MX375402 B MX 375402B
- Authority
- MX
- Mexico
- Prior art keywords
- antibody agents
- new full
- spectrum anti
- dengue antibody
- serotypes
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—RNA viruses
- C07K16/116—Togaviridae (F); Matonaviridae (F); Flaviviridae (F)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461938605P | 2014-02-11 | 2014-02-11 | |
| PCT/US2015/015510 WO2015123362A1 (en) | 2014-02-11 | 2015-02-11 | Novel full spectrum anti-dengue antibody |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2016009991A MX2016009991A (es) | 2016-10-07 |
| MX375402B true MX375402B (es) | 2025-03-06 |
Family
ID=53800606
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016009991A MX375402B (es) | 2014-02-11 | 2015-02-11 | Nuevo anticuerpo anti-dengue de espectro completo. |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US9902764B2 (enExample) |
| EP (1) | EP3104888A4 (enExample) |
| JP (1) | JP6707455B2 (enExample) |
| KR (1) | KR20160119806A (enExample) |
| CN (1) | CN106413749B (enExample) |
| AU (1) | AU2015217149B2 (enExample) |
| BR (1) | BR112016017764A2 (enExample) |
| CA (1) | CA2938495A1 (enExample) |
| IL (1) | IL246788A0 (enExample) |
| MX (1) | MX375402B (enExample) |
| SG (2) | SG10201807826XA (enExample) |
| WO (1) | WO2015123362A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3415529B1 (en) | 2007-09-26 | 2020-11-04 | Chugai Seiyaku Kabushiki Kaisha | Modified antibody constant region |
| WO2014025546A2 (en) | 2012-08-07 | 2014-02-13 | Massachusetts Institute Of Technology | Anti-dengue virus antibodies and uses thereof |
| CA2938590C (en) | 2014-02-11 | 2023-10-17 | Visterra, Inc. | Antibody molecules to dengue virus and uses thereof |
| SG10201807826XA (en) * | 2014-02-11 | 2018-10-30 | Massachusetts Inst Technology | Novel full spectrum anti-dengue antibody |
| WO2016125495A1 (en) | 2015-02-05 | 2016-08-11 | Chugai Seiyaku Kabushiki Kaisha | Antibodies comprising an ion concentration dependent antigen-binding domain, fc region variants, il-8-binding antibodies, and uses therof |
| JP7155009B2 (ja) | 2016-03-25 | 2022-10-18 | ビステラ， インコーポレイテッド | デングウイルスに対する抗体分子の製剤 |
| BR112019001902A2 (pt) | 2016-08-05 | 2019-07-09 | Chugai Seiyaku Kabushiki Kaisha | composição para profilaxia ou tratamento de doenças relacionadas à il-8 |
| SG10201607778XA (en) | 2016-09-16 | 2018-04-27 | Chugai Pharmaceutical Co Ltd | Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use |
| JP2022008719A (ja) * | 2016-11-23 | 2022-01-14 | セルヴァス エーアイ インコーポレイテッド | 疾患発症予測方法及び装置 |
| GEAP202315128A (en) | 2016-12-23 | 2023-02-10 | Serum Institute Of India Pvt Ltd | Improved methods for enhancing antibody productivity in mammalian cell culture and minimizing aggregation during downstream, formulation processes and stable antibody formulations obtained thereof |
| CA3093729A1 (en) | 2018-03-15 | 2019-09-19 | Chugai Seiyaku Kabushiki Kaisha | Anti-dengue virus antibodies having cross-reactivity to zika virus and methods of use |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4957939A (en) | 1981-07-24 | 1990-09-18 | Schering Aktiengesellschaft | Sterile pharmaceutical compositions of gadolinium chelates useful enhancing NMR imaging |
| US4472509A (en) | 1982-06-07 | 1984-09-18 | Gansow Otto A | Metal chelate conjugated monoclonal antibodies |
| US4938948A (en) | 1985-10-07 | 1990-07-03 | Cetus Corporation | Method for imaging breast tumors using labeled monoclonal anti-human breast cancer antibodies |
| US5750172A (en) | 1987-06-23 | 1998-05-12 | Pharming B.V. | Transgenic non human mammal milk |
| US5633076A (en) | 1989-12-01 | 1997-05-27 | Pharming Bv | Method of producing a transgenic bovine or transgenic bovine embryo |
| JPH049249A (ja) | 1990-04-27 | 1992-01-14 | Kusuda:Kk | 塗型剤吹き付け機 |
| ES2146648T3 (es) | 1993-03-09 | 2000-08-16 | Genzyme Corp | Procedimiento de aislamiento de proteinas de la leche. |
| US5500161A (en) | 1993-09-21 | 1996-03-19 | Massachusetts Institute Of Technology And Virus Research Institute | Method for making hydrophobic polymeric microparticles |
| US5827690A (en) | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
| JPH07299655A (ja) | 1994-04-30 | 1995-11-14 | Aisin Seiki Co Ltd | 内スプライン歯面仕上機 |
| DE19742706B4 (de) | 1997-09-26 | 2013-07-25 | Pieris Proteolab Ag | Lipocalinmuteine |
| WO2003029462A1 (en) | 2001-09-27 | 2003-04-10 | Pieris Proteolab Ag | Muteins of human neutrophil gelatinase-associated lipocalin and related proteins |
| EP1430136A1 (en) | 2001-09-27 | 2004-06-23 | Pieris ProteoLab AG | Muteins of apolipoprotein d |
| AU2003210060B2 (en) | 2002-03-22 | 2010-02-25 | Aprogen, Inc. | Humanized antibody and process for preparing same |
| US7232888B2 (en) | 2002-07-01 | 2007-06-19 | Massachusetts Institute Of Technology | Antibodies against tumor surface antigens |
| MXPA05004528A (es) | 2002-11-01 | 2005-07-26 | Glaxosmithkline Biolog Sa | Composicion inmunogenica. |
| US7622113B2 (en) * | 2003-12-08 | 2009-11-24 | The United States Of America As Represented By The Department Of Health And Human Services | Monoclonal antibodies that bind or neutralize dengue virus |
| EP2899277A1 (en) | 2004-11-26 | 2015-07-29 | Pieris AG | Compound with affinity for the cytotoxic T lymphocyte-associated antigen (CTLA-4) |
| EP1924280A4 (en) * | 2005-08-10 | 2008-12-10 | Acambis Inc | VACCINATION AGAINST DENGUE VIRUS INFECTION |
| CU23586A1 (es) | 2005-11-22 | 2010-10-30 | Ct Ingenieria Genetica Biotech | Métodos y proteínas para el tratamiento profiláctico y/o terapéutico de los cuatro serotipos del virus de dengue y otros flavivirus |
| CU23632A1 (es) | 2006-04-28 | 2011-02-24 | Ct Ingenieria Genetica Biotech | Métodos para la identificación de candidatos terapéuticos contra enfermedades causadas por flavivirus y moléculas antivirales. |
| WO2009098450A2 (en) | 2008-02-05 | 2009-08-13 | Medical Research Council | Methods and compositions |
| WO2010039154A1 (en) * | 2008-10-05 | 2010-04-08 | Board Of Trustees Of Leland Stanford Junior University | Hepatitis c antibodies and uses thereof |
| CN102272155B (zh) * | 2008-10-13 | 2018-05-25 | 生物医学研究所 | 登革热病毒中和抗体及其用途 |
| AU2009322185A1 (en) | 2008-12-05 | 2011-07-21 | Lpath, Inc. | Antibody design using anti-lipid antibody crystal structures |
| SG173482A1 (en) | 2009-02-10 | 2011-09-29 | Univ Nanyang Tech | Antibodies for diagnosis and treatment of flaviviral infections |
| EP2353609A1 (en) | 2010-02-04 | 2011-08-10 | Sanofi Pasteur | Immunization compositions and methods |
| US8637035B2 (en) | 2010-07-16 | 2014-01-28 | Academia Sinica | Anti-dengue virus antibodies |
| WO2013089647A1 (en) | 2011-12-16 | 2013-06-20 | Agency For Science, Technology And Research | Binding molecules against dengue virus and uses thereof |
| WO2013173348A1 (en) * | 2012-05-14 | 2013-11-21 | The Usa, As Represented By The Secretary, Dept. Of Health & Human Services | Cross-reactive antibodies against dengue virus and uses thereof |
| WO2014025546A2 (en) | 2012-08-07 | 2014-02-13 | Massachusetts Institute Of Technology | Anti-dengue virus antibodies and uses thereof |
| SG10201807826XA (en) | 2014-02-11 | 2018-10-30 | Massachusetts Inst Technology | Novel full spectrum anti-dengue antibody |
| CA2938590C (en) * | 2014-02-11 | 2023-10-17 | Visterra, Inc. | Antibody molecules to dengue virus and uses thereof |
-
2015
- 2015-02-11 SG SG10201807826XA patent/SG10201807826XA/en unknown
- 2015-02-11 MX MX2016009991A patent/MX375402B/es active IP Right Grant
- 2015-02-11 BR BR112016017764A patent/BR112016017764A2/pt not_active Application Discontinuation
- 2015-02-11 SG SG11201606163QA patent/SG11201606163QA/en unknown
- 2015-02-11 KR KR1020167024129A patent/KR20160119806A/ko not_active Ceased
- 2015-02-11 EP EP15749661.3A patent/EP3104888A4/en not_active Withdrawn
- 2015-02-11 CN CN201580008265.9A patent/CN106413749B/zh active Active
- 2015-02-11 AU AU2015217149A patent/AU2015217149B2/en active Active
- 2015-02-11 US US14/620,144 patent/US9902764B2/en active Active
- 2015-02-11 JP JP2016550573A patent/JP6707455B2/ja active Active
- 2015-02-11 WO PCT/US2015/015510 patent/WO2015123362A1/en not_active Ceased
- 2015-02-11 CA CA2938495A patent/CA2938495A1/en active Pending
-
2016
- 2016-07-14 IL IL246788A patent/IL246788A0/en unknown
-
2018
- 2018-01-11 US US15/868,328 patent/US10519220B2/en active Active
-
2019
- 2019-12-26 US US16/727,561 patent/US11421018B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20200207841A1 (en) | 2020-07-02 |
| CA2938495A1 (en) | 2015-08-20 |
| JP2017507131A (ja) | 2017-03-16 |
| CN106413749B (zh) | 2022-04-05 |
| US11421018B2 (en) | 2022-08-23 |
| CN106413749A (zh) | 2017-02-15 |
| IL246788A0 (en) | 2016-08-31 |
| US20180237504A1 (en) | 2018-08-23 |
| AU2015217149B2 (en) | 2020-09-10 |
| SG10201807826XA (en) | 2018-10-30 |
| WO2015123362A1 (en) | 2015-08-20 |
| SG11201606163QA (en) | 2016-08-30 |
| KR20160119806A (ko) | 2016-10-14 |
| US20150368321A1 (en) | 2015-12-24 |
| JP6707455B2 (ja) | 2020-06-10 |
| US10519220B2 (en) | 2019-12-31 |
| MX2016009991A (es) | 2016-10-07 |
| BR112016017764A2 (pt) | 2017-10-10 |
| EP3104888A1 (en) | 2016-12-21 |
| EP3104888A4 (en) | 2017-08-09 |
| US9902764B2 (en) | 2018-02-27 |
| AU2015217149A1 (en) | 2016-09-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2019008736A (es) | Anticuerpos anti-virus del dengue y usos de los mismos. | |
| JOP20200312A1 (ar) | الأجسام المضادة للعامل xi وطرق الاستخدام | |
| SG10201807826XA (en) | Novel full spectrum anti-dengue antibody | |
| PH12021550337A1 (en) | Anti-gdf15 antibodies, compositions and methods of use | |
| EA201792221A1 (ru) | Антитела против сортилина и способы их применения | |
| MX2022002364A (es) | Anticuerpos anti-pd-l1. | |
| MX388181B (es) | Anticuerpos anti-pd-1. | |
| EA202190609A1 (ru) | Антитела против hla-g, композиции, содержащие антитела против hla-g, и способы применения антител против hla-g | |
| MX2022012749A (es) | Moleculas de union a linfopoyetina estromal timica (tslp) y metodos de uso de las moleculas. | |
| EA201891992A1 (ru) | Химерные рецепторы и способы их применения | |
| EA201791270A1 (ru) | Модифицированные april-связывающие антитела | |
| EA201791485A1 (ru) | Анти-cd47-антитела и их применения | |
| PH12016501366A1 (en) | Novel anti-baff antibodies | |
| EA201890305A1 (ru) | Гуманизированные или химерные cd3-антитела | |
| EA201690167A1 (ru) | Гуманизованные или химерные антитела к cd3 | |
| EA201890302A1 (ru) | Химерные рецепторы антигенов на основе однодоменных антител и способы их применения | |
| MX2019005426A (es) | Anticuerpos anti-lag3 y fragmentos de union a antigeno. | |
| TN2018000076A1 (en) | Thymic stromal lymphopoietin (tslp)-binding molecules and methods of using the molecules | |
| MX2019007554A (es) | Proteínas de uníon al antígeno anti-neuropilina, y sus métodos de uso. | |
| CL2016003040A1 (es) | Moléculas de unión tri-específicas y métodos de uso de las mismas. | |
| JO3791B1 (ar) | تركيبات و طرق الأجسام المضادة المستهدفة لـ bmp6 | |
| EA201590918A1 (ru) | Антитела к bmp-6 | |
| EA201791691A1 (ru) | ОДНОДОМЕННЫЕ АНТИТЕЛА, НАПРАВЛЕННЫЕ НА CD1d | |
| EA201990895A1 (ru) | Антитела к о1 и варианты их применения | |
| EA201891529A1 (ru) | Композиции и способы обнаружения и лечения рака яичников |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |